Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer

We report a comprehensive molecular analysis of 34 cases of small cell carcinoma (SCC) and 84 cases of conventional urothelial carcinoma (UC), with The Cancer GenomeAtlas cohort of 408 conventional UCbladder cancers used as the reference. SCCs showed mutational landscapes characterized by nearly uniforminactivation of TP53 and were dominated by Sanger mutation signature 3 associated with loss of BRCA1/2 function. SCCs were characterized by downregulation of luminal and basal markers and were referred to as double-negative. Transcriptome analyses indicated that SCCs displayed lineage plasticity driven by a urothelial-to-neural phenotypic switch with a dysregulated epithelial-to-mesenchymal transition network. SCCs were depleted of immune cells, and expressed high levels of the immune checkpoint receptor, adenosine receptor A2A(ADORA2A), which is a potent inhibitor o fimmune infiltration. Our observations have important implications for the prognostication and development of more effective therapies for this lethal bladder cancer variant.